Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03795376

Dat'Aids Prevention

DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis

Recruiting

Interested in participating?

Request Info

Key information

Conditions

HIV Prevention

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Nord Franche Comté, Belfort, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female over 18 years old,
  • HIV negative
  • Attending for :
  • HIV screening
  • Hepatitis screening
  • STI screening / treatment
  • Blood, body fluid or sexual exposure
  • Post-exposure prophylaxis
  • Pre-exposure prophylaxis
  • Signed consent

Exclusion criteria

  • HIV-infection
  • Refusal to participate

Treatment and study plan

Primary outcomes

  1. Number of patients enrolled for HIV prevention in the cohort

    Time frame: From date of enrollment, through study completion, an average of 1 year

    Demographics, risk factors clinical and biological characteristics, treatment of patients enrolled for HIV prevention in the cohort

Secondary outcomes

  1. Proportion of persons enrolled for pre-exposure prophylaxis in the cohort

    Time frame: From date of enrollment, through study completion, an average of 1 year

    Demographics, risk factors clinical and biological characteristics, treatment of patients attending for pre-exposure prophylaxis in the cohort

  2. Proportion of persons enrolled for post-exposure prophylaxis in the cohort

    Time frame: From date of enrollment, through study completion, an average of 1 year

    Demographics, risk factors clinical and biological characteristics, treatment of patients attending for post-exposure prophylaxis in the cohort

  3. Proportion of persons enrolled for hepatitis screening in the cohort

    Time frame: From date of enrollment, through study completion, an average of 1 year

    Demographics, risk factors clinical and biological characteristics, treatment of patients attending for hepatitis screening in the cohort

  4. Proportion of persons enrolled for pre-exposure prophylaxis in the cohort according to national French guidelines

    Time frame: From date of enrollment, through study completion, an average of 1 year

    Adequation between prevention practices and guidelines

  5. Proportion of persons enrolled for post-exposure prophylaxis in the cohort according to national French guidelines

    Time frame: From date of enrollment, through study completion, an average of 1 year

    Adequation between prevention practices and guidelines

  6. Incidence of STIs

    Time frame: From date of enrollment, through study completion, an average of 1 year

  7. Incidence of hepatitis

    Time frame: From date of enrollment, through study completion, an average of 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Pascal Pugliese, MD

CONTACT

[email protected]

0033492035802

Solène Secher

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

DatAids

Other

Registry information

Official study title

HIV Prevention in France : "Dat'AIDS Prevention"

Important dates

Study start
2019
Primary completion
2030
Study completion
2030
First posted
Jan 7, 2019
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.